United Therapeutics (UTHR) Upgraded to Buy by ValuEngine

ValuEngine upgraded shares of United Therapeutics (NASDAQ:UTHR) from a hold rating to a buy rating in a report issued on Thursday.

A number of other analysts have also recently issued reports on the stock. Zacks Investment Research upgraded shares of United Therapeutics from a strong sell rating to a hold rating in a research note on Monday, October 9th. Oppenheimer reiterated a buy rating on shares of United Therapeutics in a research note on Friday, September 8th. Cowen reiterated a hold rating and issued a $129.00 target price on shares of United Therapeutics in a research note on Friday, October 27th. HC Wainwright reiterated a hold rating and issued a $95.00 target price on shares of United Therapeutics in a research note on Thursday, October 26th. Finally, TheStreet cut shares of United Therapeutics from a b- rating to a c rating in a research note on Friday, September 29th. Four investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and three have given a buy rating to the company. The company currently has an average rating of Hold and a consensus target price of $136.10.

Shares of United Therapeutics (NASDAQ UTHR) opened at $133.32 on Thursday. The company has a market cap of $5,760.89, a P/E ratio of 11.76 and a beta of 1.42. United Therapeutics has a fifty-two week low of $112.01 and a fifty-two week high of $169.89.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, October 25th. The biotechnology company reported $6.27 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $4.01 by $2.26. The firm had revenue of $445.50 million during the quarter, compared to analysts’ expectations of $426.43 million. United Therapeutics had a net margin of 30.50% and a return on equity of 26.24%. The company’s revenue was up 9.1% compared to the same quarter last year. During the same period in the previous year, the company earned $4.23 earnings per share. equities research analysts forecast that United Therapeutics will post 12.45 EPS for the current fiscal year.

In related news, Director Christopher Causey sold 580 shares of the company’s stock in a transaction dated Thursday, September 7th. The shares were sold at an average price of $134.48, for a total transaction of $77,998.40. Following the transaction, the director now owns 3,295 shares in the company, valued at approximately $443,111.60. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Martine A. Rothblatt sold 1,232 shares of the company’s stock in a transaction dated Thursday, September 7th. The stock was sold at an average price of $133.32, for a total transaction of $164,250.24. Following the transaction, the chief executive officer now owns 2,301 shares in the company, valued at approximately $306,769.32. The disclosure for this sale can be found here. Insiders sold a total of 23,900 shares of company stock worth $2,919,517 in the last three months. Insiders own 7.80% of the company’s stock.

A number of large investors have recently made changes to their positions in the business. Sage Capital Advisors llc bought a new stake in United Therapeutics during the 3rd quarter worth about $3,162,000. Public Employees Retirement System of Ohio increased its stake in shares of United Therapeutics by 10.0% in the 3rd quarter. Public Employees Retirement System of Ohio now owns 20,823 shares of the biotechnology company’s stock valued at $2,440,000 after acquiring an additional 1,898 shares during the last quarter. Sterling Capital Management LLC increased its stake in shares of United Therapeutics by 6.1% in the 3rd quarter. Sterling Capital Management LLC now owns 18,534 shares of the biotechnology company’s stock valued at $2,172,000 after acquiring an additional 1,060 shares during the last quarter. California Public Employees Retirement System increased its stake in shares of United Therapeutics by 1.5% in the 3rd quarter. California Public Employees Retirement System now owns 133,793 shares of the biotechnology company’s stock valued at $15,679,000 after acquiring an additional 1,993 shares during the last quarter. Finally, Asset Management One Co. Ltd. increased its stake in shares of United Therapeutics by 23.6% in the 3rd quarter. Asset Management One Co. Ltd. now owns 82,688 shares of the biotechnology company’s stock valued at $9,722,000 after acquiring an additional 15,805 shares during the last quarter. 99.83% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: This news story was originally published by Community Financial News and is the sole property of of Community Financial News. If you are reading this news story on another site, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be accessed at https://www.com-unik.info/2017/12/04/united-therapeutics-uthr-upgraded-to-buy-by-valuengine.html.

About United Therapeutics

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for United Therapeutics (NASDAQ:UTHR)

What are top analysts saying about United Therapeutics Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for United Therapeutics Corporation and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit